10:50 | 08/04/2020 Cooperation
(VEN) - Pharmaceutical multinational GlaxoSmithKline (GSK) is closely monitoring the COVID-19 pandemic and supporting global efforts to tackle it with real and meaningful actions, senior executives say.
|GSK makes its vaccine adjuvant technology available to support their respective Covid-19 vaccine research programmes|
GSK has donated $10 million to WHO and the UN Foundation’s COVID-19 Solidarity Response Fund to support them and other partners to detect and manage the pandemic, particularly where the needs are the greatest.
Besides, the company is working with five partner companies and research groups across the world, including in the USA and China. This builds on its previous announcements on partnerships with the University of Queensland and Clover Biopharmaceuticals to make its vaccine adjuvant technology available to support their respective COVID-19 vaccine research programmes.
The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced, and therefore contributing to the protection of more people.
A GSK statement also says that it is entering a new collaborative research effort, the COVID-19 Therapeutics Accelerator, by making available compounds from its libraries for screening, with the aim of bringing forward the most promising molecules that could be used to treat cases of COVID-19.
Dan Millard, GSK Vietnam Chief Representative, said the company in global was also evaluating its marketed medicines and those in development to determine if any could be used beyond their current indications, and evaluating options to make available its specialised laboratory space to help with research and testing in dealing with the COVID-19 pandemic.
In addition, GSK is also donating surplus reagents to countries to support diagnostic testing, preparing to do the same for surplus personal protective equipment (PPE) and have initiated new volunteering processes for employees to enable those with medical or specialist expertise to provide support to frontline health workers and national governments.
GSK Consumer Healthcare in global is prioritising actions in its supply chain to deliver more consumer products that are in high demand due to COVID-19. This includes increasing production for pain relief brands such as Paracetamol, multi-vitamins and dietary supplements.
“GSK in global continues to monitor the situation closely and take actions to develop our response to the pandemic. In doing so, we will continue to put the needs of patients and our people first at all times,” Millard added.